Cargando…
Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs?
Current treatment of chronic diseases includes, among others, application of cytokines, monoclonal antibodies, cellular therapies, and immunostimulants. As all the underlying mechanisms of a particular diseases are not always fully clarified, treatment can be inefficient and associated with various,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284804/ https://www.ncbi.nlm.nih.gov/pubmed/32344935 http://dx.doi.org/10.3390/microorganisms8050621 |
_version_ | 1783544553736765440 |
---|---|
author | Hrdý, Jiří Súkeníková, Lenka Petrásková, Petra Novotná, Olga Kahoun, David Petříček, Miroslav Chroňáková, Alica Petříčková, Kateřina |
author_facet | Hrdý, Jiří Súkeníková, Lenka Petrásková, Petra Novotná, Olga Kahoun, David Petříček, Miroslav Chroňáková, Alica Petříčková, Kateřina |
author_sort | Hrdý, Jiří |
collection | PubMed |
description | Current treatment of chronic diseases includes, among others, application of cytokines, monoclonal antibodies, cellular therapies, and immunostimulants. As all the underlying mechanisms of a particular diseases are not always fully clarified, treatment can be inefficient and associated with various, sometimes serious, side effects. Small secondary metabolites produced by various microbes represent an attractive alternative as future anti-inflammatory drug leads. Compared to current drugs, they are cheaper, can often be administered orally, but still can keep a high target-specificity. Some compounds produced by actinomycetes or fungi have already been used as immunomodulators—tacrolimus, sirolimus, and cyclosporine. This work documents strong anti-inflammatory features of another secondary metabolite of streptomycetes—manumycin-type polyketides. We compared the effect of four related compounds: manumycin A, manumycin B, asukamycin, and colabomycin E on activation and survival of human monocyte/macrophage cell line THP-1. The anti-cancer effect of manucycine A has been demonstrated; the immunomodulatory capacities of manumycin A are obvious when using micromolar concentrations. The application of all four compounds in 0.25–5 μM concentrations leads to efficient, concentration-dependent inhibition of IL-1β and TNF expression in THP-1 upon LPS stimulation, while the three latter compounds show a significantly lower pro-apoptotic effect than manumycin A. We have demonstrated the anti-inflammatory capacity of selected manumycin-type polyketides. |
format | Online Article Text |
id | pubmed-7284804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72848042020-06-15 Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs? Hrdý, Jiří Súkeníková, Lenka Petrásková, Petra Novotná, Olga Kahoun, David Petříček, Miroslav Chroňáková, Alica Petříčková, Kateřina Microorganisms Article Current treatment of chronic diseases includes, among others, application of cytokines, monoclonal antibodies, cellular therapies, and immunostimulants. As all the underlying mechanisms of a particular diseases are not always fully clarified, treatment can be inefficient and associated with various, sometimes serious, side effects. Small secondary metabolites produced by various microbes represent an attractive alternative as future anti-inflammatory drug leads. Compared to current drugs, they are cheaper, can often be administered orally, but still can keep a high target-specificity. Some compounds produced by actinomycetes or fungi have already been used as immunomodulators—tacrolimus, sirolimus, and cyclosporine. This work documents strong anti-inflammatory features of another secondary metabolite of streptomycetes—manumycin-type polyketides. We compared the effect of four related compounds: manumycin A, manumycin B, asukamycin, and colabomycin E on activation and survival of human monocyte/macrophage cell line THP-1. The anti-cancer effect of manucycine A has been demonstrated; the immunomodulatory capacities of manumycin A are obvious when using micromolar concentrations. The application of all four compounds in 0.25–5 μM concentrations leads to efficient, concentration-dependent inhibition of IL-1β and TNF expression in THP-1 upon LPS stimulation, while the three latter compounds show a significantly lower pro-apoptotic effect than manumycin A. We have demonstrated the anti-inflammatory capacity of selected manumycin-type polyketides. MDPI 2020-04-25 /pmc/articles/PMC7284804/ /pubmed/32344935 http://dx.doi.org/10.3390/microorganisms8050621 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hrdý, Jiří Súkeníková, Lenka Petrásková, Petra Novotná, Olga Kahoun, David Petříček, Miroslav Chroňáková, Alica Petříčková, Kateřina Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs? |
title | Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs? |
title_full | Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs? |
title_fullStr | Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs? |
title_full_unstemmed | Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs? |
title_short | Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs? |
title_sort | inhibition of pro-inflammatory cytokines by metabolites of streptomycetes—a potential alternative to current anti-inflammatory drugs? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284804/ https://www.ncbi.nlm.nih.gov/pubmed/32344935 http://dx.doi.org/10.3390/microorganisms8050621 |
work_keys_str_mv | AT hrdyjiri inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs AT sukenikovalenka inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs AT petraskovapetra inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs AT novotnaolga inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs AT kahoundavid inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs AT petricekmiroslav inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs AT chronakovaalica inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs AT petrickovakaterina inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs |